{
    "clinical_study": {
        "@rank": "148093", 
        "acronym": "AZD3293TQT", 
        "arm_group": [
            {
                "arm_group_label": "AZD3293 dose A", 
                "arm_group_type": "Experimental", 
                "description": "AZD3293 therapeutic dose oral solution (low dose)"
            }, 
            {
                "arm_group_label": "AZD3293 dose B", 
                "arm_group_type": "Experimental", 
                "description": "AZD3293 supratherapeutic dose oral solution (high dose)"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo oral solution"
            }, 
            {
                "arm_group_label": "Moxifloxacin", 
                "arm_group_type": "Active Comparator", 
                "description": "Moxifloxacin tablet"
            }
        ], 
        "brief_summary": {
            "textblock": "A thorough QT study of AZD3293"
        }, 
        "brief_title": "AZD3293 Thorough QT Study in Healthy Male Volunteers", 
        "completion_date": {
            "#text": "April 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Alzheimer's Disease", 
        "condition_browse": {
            "mesh_term": "Alzheimer Disease"
        }, 
        "detailed_description": {
            "textblock": "A Single-Center, Randomized, Double-Blinded, Placebo-Controlled, 4-way Cross-over Study to\n      Assess the Effect of a Single Oral Dose of AZD3293 Administration on QTc Interval Compared\n      to Placebo, Using Open-Label AVELOX (moxifloxacin) as a Positive Control, in Healthy Male\n      Subjects"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Provision of signed, written and dated informed consent prior to any study-specific\n             procedures\n\n          2. Healthy male subjects must be able to understand and be willing to comply with study\n             procedures, restrictions and requirements\n\n          3. Healthy male subjects aged 18 to 55 years\n\n          4. Body weight \u2265 50 to \u2264 100 kg and body mass index (BMI) \u226519 to \u226430\n\n          5. Clinically normal findings on physical examination in relation to age, as judged by\n             the investigator.\n\n        Exclusion Criteria:\n\n          1. History of any clinically significant disease or disorder which may either put the\n             subject at risk because of participation in the study, or influence the results or\n             the subject's ability to participate in the study\n\n          2. History or presence of gastrointestinal, hepatic or renal disease or any other\n             condition known to interfere with absorption, distribution, metabolism or excretion\n             of drugs\n\n          3. History of previous or ongoing psychiatric disease/condition including psychosis,\n             affective disorder, anxiety disorder, borderline state and personality disorder\n\n          4. History of neurologic disease, including seizures (with the exception of febrile\n             infantile seizures), recent memory impairment or clinically significant head injury\n\n          5. History of psychotic disorder among first degree relatives"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "55 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "52", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "January 17, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02040987", 
            "org_study_id": "D5010C00008"
        }, 
        "intervention": [
            {
                "arm_group_label": "AZD3293 dose A", 
                "description": "AZD3293 oral solution - one single dose (low dose).", 
                "intervention_name": "AZD3293", 
                "intervention_type": "Drug", 
                "other_name": "beta secretase inhibitor"
            }, 
            {
                "arm_group_label": "AZD3293 dose B", 
                "description": "AZD3293 oral solution - one single dose (high dose).", 
                "intervention_name": "AZD3293", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "Placebo oral solution - one single dose", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Moxifloxacin", 
                "description": "Moxifloxacin tablet - one single dose", 
                "intervention_name": "Moxifloxacin", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Moxifloxacin", 
                "Norgestimate, ethinyl estradiol drug combination"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": "Thorough QT study", 
        "lastchanged_date": "April 8, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Baltimore", 
                    "country": "United States", 
                    "state": "Maryland"
                }, 
                "name": "Research Site"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "4", 
        "official_title": "A Single-Center, Randomized, Double-Blinded, Placebo-Controlled, 4-way Cross-over Study to Assess the Effect of a Single Oral Dose of AZD3293 Administration on QTc Interval Compared to Placebo, Using Open-Label AVELOX (Moxifloxacin) as a Positive Control, in Healthy Male Subjects", 
        "other_outcome": {
            "description": "The heart rate corrected QT (QTcF) will be calculated using Fridericia's formula", 
            "measure": "The relationship between plasma concentrations of AZD3293 and changes in QTcF parameters", 
            "safety_issue": "Yes", 
            "time_frame": "Up to 69 days"
        }, 
        "overall_official": {
            "affiliation": "Parexel ECPU Baltimore", 
            "last_name": "Ronald Goldwater, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "United States: Institutional Review Board"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "April 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The heart rate corrected QT (QTcF) will be calculated using Fridericia's formula", 
            "measure": "The effect of a single dose of AZD3293 low dose and high dose on the change in time-matched QTcF intervals compared with placebo.", 
            "safety_issue": "Yes", 
            "time_frame": "Up to 69 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02040987"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "The heart rate corrected QT (QTcF) will be calculated using Fridericia's formula.", 
                "measure": "The effect of a single oral dose of moxifloxacin on the changes in time-matched QTcF intervals compared with placebo.", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 69 days"
            }, 
            {
                "description": "Physical examination, electrocardiogram, pulse and blood pressure, weight and laboratory variables", 
                "measure": "The safety and tolerability of AZD3293 in healthy male subjects by assessing a panel of adverse events measures", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 69 days"
            }, 
            {
                "description": "AUC(0-t): Area under the concentration versus time curve from time 0 to the time of the last quantifiable concentration to be calculated by a combination of linear and logarithmic trapezoidal methods (linear up-log down) Cmax: Maximum observed plasma concentration obtained directly from the concentration vs. time data tmax: Time to reach Cmax following dose, obtained directly from the concentration vs. time data", 
                "measure": "Plasma concentrations, AUC, Cmax and tmax of single dose AZD3293 and moxifloxacin in healthy male subjects", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 69 days"
            }, 
            {
                "description": "RR: The time between corresponding points on 2 consecutive R waves on ECG. PR: ECG interval measured from the onset of the P wave to the onset of the QRS complex. QRS: ECG interval measured from the onset of the QRS complex to the J point. QT: ECG interval measured from the onset of the QRS complex to the offset of the T wave. QTcB: The heart rate corrected QT calculated using Bazett's formula.", 
                "measure": "The effect of AZD3293 on additional electrocardiogram (ECG) variables (heart rate, RR, PR, QRS, QT and QTcB)", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 69 days"
            }
        ], 
        "source": "AstraZeneca", 
        "sponsors": {
            "collaborator": {
                "agency": "Parexel", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "AstraZeneca", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}